Status:
COMPLETED
XELOX for Metastatic Breast Cancer
Lead Sponsor:
University of Wisconsin, Madison
Collaborating Sponsors:
Sanofi
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination i...
Eligibility Criteria
Inclusion
- preserved organ function
- good performance status
- no more than one prior therapy
- no active brain metastasis
Exclusion
- No prior capecitabine or oxaliplatin
- no con-current therapy
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2006
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00204776
Start Date
March 1 2005
End Date
November 1 2006
Last Update
December 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792